Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Procter & Gamble Hygiene and Health Care Limited (500459) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Procter & Gamble Hygiene and Health Care Limited ₹2,989, price ₹6,648, upside -55.0%, quality 91 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
PG
Broad data
Sep 24, 2026
Procter & Gamble Hygiene and Health Care Limited
500459 · BSEQuality Too ExpensiveExcellent quality, but the valuation looks stretched.
!Fair value ₹2,989 · Strongly overvalued (−55.0%)
✓Quality 91/100
✓Healthy Growth (revenue YoY +26.9 %/yr)
✓Highly profitable · 20.0% net margin (FY2025)
✓Low debt · generates free cash flow
✓Wide moat 78/100
Watch Procter & Gamble Hygiene and Health Care Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹6,648 – ₹17,809 · fair‑value band ₹2,027 – ₹4,254 · the ₹6,648 price screens above the ₹2,989 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast moving consumer goods in the femcare and healthcare businesses in India.
Show more
Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast moving consumer goods in the femcare and healthcare businesses in India. The company offers health care products, including ointment and creams, and cough drops and tablets; and hygiene products comprising feminine hygiene and other skin care hygiene products under the Vicks, Whisper, and Old Spice brand names. Procter & Gamble Hygiene and Health Care Limited sells its products through retail operations, including mass merchandisers, as well as grocery, membership club, drug, department, and high frequency stores. The company was founded in 1964 and is headquartered in Mumbai, India. Procter & Gamble Hygiene and Health Care Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Stock analysis
Procter & Gamble Hygiene and Health Care Limited (500459) currently trades at ₹6,648, while our model-based Fair Value estimate is ₹2,989, 55.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹3,111 per share, and 0 of the 24 models we run sit above the ₹6,648 price.
Bear case: the Economic Profit group reads lowest at ₹565.18, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹2,027 (bear) to ₹4,254 (bull), the price of ₹6,648 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 91/100 (high quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Procter & Gamble Hygiene and Health Care Limited reported revenue of ₹42.8B in FY2025 versus ₹39.0B in FY2021, a compound +2.4%/yr. Reported net income was ₹8.6B in FY2025, compounding +10.4%/yr from FY2021.
Key figures
Market cap ₹341B (≈ $3.5B) · P/E ratio 80.4 · P/S ratio 16.1 · EPS (TTM) ₹130.84 · Net margin 20.0% · Return on assets (EBIT) 49.2% · Free cash flow ₹8.7B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −29% fair-value upside, at −55%, 500459 screens richer than that median.
Fair Value models
Bear ₹2,027
Fair Value ₹2,989
Bull ₹4,254
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹98.94 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
₹1,966
₹2,945
₹4,382
80
Growth DCF
₹1,991
₹2,851
₹4,035
79
Owner Earnings
₹1,902
₹2,848
₹4,236
76
All 24 models by family
DCF Models
FCF DCF
₹1,966
₹2,945
₹4,382
80
Owner Earnings
₹1,902
₹2,848
₹4,236
76
5Y Revenue Exit
₹1,312
₹1,857
₹2,531
73
5Y EBITDA Exit
₹2,042
₹3,225
₹4,598
75
5Y P/E Exit
₹2,271
₹3,654
₹5,103
70
10Y Revenue Exit
₹1,514
₹2,063
₹2,765
67
10Y EBITDA Exit
₹1,995
₹2,991
₹4,308
68
10Y P/E Exit
₹2,138
₹3,283
₹4,686
64
Earnings-Based
Graham-Dodd
₹1,134
₹3,556
₹4,733
64
Lynch FV
₹776.55
₹1,109
₹1,442
61
PEG = 1.0
₹776.55
₹1,109
₹1,442
57
EPV
₹1,694
₹1,945
₹2,161
71
Multiples
P/E Multiple
₹2,627
₹3,503
₹4,379
63
P/S Multiple
₹1,001
₹1,334
₹1,668
58
P/B Multiple
₹605.36
₹807.15
₹1,009
55
EV/EBIT
₹2,924
₹3,862
₹4,800
66
EV/EBITDA
₹2,332
₹3,074
₹3,815
67
EV/Revenue
₹984.08
₹1,359
₹1,735
54
Asset-Based
NCAV (Graham)
₹73.38
₹98.33
₹146.75
54
Growth DCF
Growth DCF
₹1,991
₹2,851
₹4,035
79
Rev-Margin DCF
₹1,312
₹1,878
₹2,538
73
Economic Profit
Residual Income
₹447.74
₹565.18
₹1,036
73
ROIC Compounder
₹1,704
₹1,968
₹2,202
72
Growth Earnings
Growth-Adj P/E
₹2,178
₹3,111
₹4,045
67
Notify me when 500459 reaches fair value
Put 500459 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
91/100
Of which business quality 87 · Market factors (momentum, volatility) 30
Profitability
96
Margins and returns on capital today
Quality Growth
82
Are margins and returns improving?
Cashflow
75
Earnings quality: real cash, not paper profit
Fin. Strength
92
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
90
Calm price path (market factor)
Momentum
7
Price trend over the last 3–12 months (market factor)
52W Momentum
0
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8.3% vs 7.2%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 27%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +14.8% a year for the price.
500459 screens overvalued: fair value 55% below the price. Compare with Colgate-Palmolive Company →
Compare Procter & Gamble Hygiene and Health Care Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Other · 125 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Other median · lower = cheaper
Context: sector, industry, market
- Is the Materials sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Colgate-Palmolive Company CL | $86.52 | $56.16 | −35% |
| Hindustan Unilever Limited HINDUNILVR | ₹1,836 | ₹775.25 | −58% |
| Kenvue Inc KVUE | $17.80 | $12.72 | −29% |
| The Estée Lauder Companies Inc EL | $90.19 | $44.21 | −51% |
| Kimberly-Clark Corporation KMB | $98.77 | $83.77 | −15% |
| Henkel AG HEN | €66.35 | €82.61 | +25% |
| Church & Dwight Co CHD | $95.62 | $65.04 | −32% |
| Beiersdorf Aktiengesellschaft, BEI | €75.40 | €69.09 | −8% |
| Puig Brands, S.A PUIG | €17.84 | €24.28 | +36% |
| Marico Limited MARICO | ₹781.35 | ₹493.84 | −37% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Procter & Gamble Hygiene and Health Care Limited (500459) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹2,989 versus a price of ₹6,648, about −55% upside (overvalued).
What is the fair value of 500459?
Our model-based fair value for Procter & Gamble Hygiene and Health Care Limited is ₹2,989 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹6,648.
What is the quality score of 500459?
Procter & Gamble Hygiene and Health Care Limited has a Quality Score of 91/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Procter & Gamble Hygiene and Health Care Limited (500459)?
Our model-based price target is the fair value of ₹2,989 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario ₹2,027, optimistic scenario ₹4,254. It is a calculation from audited fundamentals, not an analyst target.
What is the Procter & Gamble Hygiene and Health Care Limited stock forecast for 2026?
Our models put fair value at ₹2,989, about −55% upside versus a price of ₹6,648 (overvalued). Cautious scenario ₹2,027, optimistic scenario ₹4,254. The calculation is refreshed regularly with new filings.
What growth is priced into Procter & Gamble Hygiene and Health Care Limited (500459)?
For today's price to be fair in a discounted-cash-flow model, Procter & Gamble Hygiene and Health Care Limited would have to grow free cash flow by +19.5 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 500459 use?
Our models discount Procter & Gamble Hygiene and Health Care Limited at 12.4 %: a base by market capitalisation (mid), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Procter & Gamble Hygiene and Health Care Limited that is +19.5 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Procter & Gamble Hygiene and Health Care Limited (500459) delivered so far?
Over the past 5 years revenue at Procter & Gamble Hygiene and Health Care Limited grew +3.7 % a year. The price currently implies +19.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Procter & Gamble Hygiene and Health Care Limited (500459) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Procter & Gamble Hygiene and Health Care Limited (+19.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Procter & Gamble Hygiene and Health Care Limited (500459)?
The free-cash-flow yield on the price is 4.05 %: that much free cash flow Procter & Gamble Hygiene and Health Care Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Procter & Gamble Hygiene and Health Care Limited (500459)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Procter & Gamble Hygiene and Health Care Limited it is ₹2,989 per share (as of Sep 24, 2026), against a price of ₹6,648. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Procter & Gamble Hygiene and Health Care Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 500459 trades above its calculated fair value: price ₹6,648, fair value ₹2,989, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 500459?
No. The price is what the market pays today (₹6,648); the fair value is what the company's own numbers justify (₹2,989). For Procter & Gamble Hygiene and Health Care Limited the two are ₹3,659 per share apart. That gap is exactly why we show both numbers side by side.
How much is Procter & Gamble Hygiene and Health Care Limited worth?
The market values Procter & Gamble Hygiene and Health Care Limited at about ₹341B (market capitalisation, as of Sep 24, 2026). Per share that is ₹6,648; our models calculate a fair value of ₹2,989 per share.
What do the bullish and bearish scenarios say about 500459?
Our models span a range for Procter & Gamble Hygiene and Health Care Limited: cautious scenario ₹2,027, base ₹2,989, optimistic ₹4,254 per share (as of Sep 24, 2026, price ₹6,648). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 500459?
Procter & Gamble Hygiene and Health Care Limited trades at a price-to-earnings ratio of 80.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2,989 is built from several models across several years. Other multiples: P/B 0.5.
How far is 500459 from its 52-week high?
Procter & Gamble Hygiene and Health Care Limited trades at ₹6,648, about 53% below its 52-week high of ₹14,241 and at the low of ₹6,648 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2,989 is for.
Which stocks are comparable to Procter & Gamble Hygiene and Health Care Limited?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, The Estée Lauder Companies Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Procter & Gamble Hygiene and Health Care Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹6,648, calculated fair value ₹2,989 (−55%), Quality Score 91/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 500459 calculated?
We run Procter & Gamble Hygiene and Health Care Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹2,989, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Procter & Gamble Hygiene and Health Care Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Procter & Gamble Hygiene and Health Care Limited (500459)?
The closing price on Oct 1, 2026 was ₹6,648. Our model-based fair value is ₹2,989, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Procter & Gamble Hygiene and Health Care Limited right now?
A high-quality business (quality 91/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (₹4,254). The favourable scenario is already priced in. A fairly wide model range (₹2,027 to ₹4,254) leaves room in how you read the outcome.
Key figures of Procter & Gamble Hygiene and Health Care Limited
How large is the market capitalisation of Procter & Gamble Hygiene and Health Care Limited (500459)?
The market capitalisation of Procter & Gamble Hygiene and Health Care Limited is ₹341B (≈ $3.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Procter & Gamble Hygiene and Health Care Limited (500459)?
The price-to-sales ratio of Procter & Gamble Hygiene and Health Care Limited is 16.1 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Procter & Gamble Hygiene and Health Care Limited (500459)?
Earnings per share at Procter & Gamble Hygiene and Health Care Limited are ₹130.84 (price ÷ EPS = P/E 80.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Procter & Gamble Hygiene and Health Care Limited (500459)?
The net margin of Procter & Gamble Hygiene and Health Care Limited is 20.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Procter & Gamble Hygiene and Health Care Limited (500459)?
On an EBIT basis the return on assets of Procter & Gamble Hygiene and Health Care Limited is 49.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
Free · no account needed
Watch Procter & Gamble Hygiene and Health Care Limited in the live analysis
One click puts Procter & Gamble Hygiene and Health Care Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.